Another lab study found that the Omicron Covid variant of vaccines is’markely’ less effective at protecting against infection in comparison to other major ones after just two doses.

Columbia University researchers tested the mutant strain against the blood of people vaccinated with two doses of the four big brands — Pfizer, Moderna, Johnson & Johnson and AstraZeneca.

The researchers also examined people who were given one of two mRNA vaccination boosters in their research. However, this study hasn’t been published in any scientific journals or peer-reviewed.

The Omicron neutralizing antibodies showed a 21-fold decrease in Omicron’s levels after receiving two doses Pfizer, compared with the original strain. Moderna’s jabs caused an 8.6-fold increase.  

Antibodies were so low two-dose course of Johnson & Johnson and AstraZeneca’s jabs that they were undetectable, suggesting they offer virtually no protection against infection. 

However, scientists warn that antibody studies don’t take into account T and B cell responses to Covid. These cells are crucial in preventing severe symptoms from developing but can be difficult to measure.

MailOnline has been told that experts believe Omicron can be countered by other components of the immune response, either from vaccination or an older infection. They also recommend keeping hospitalisations under the previous wave. 

The number of antibodies against Omicron found in patients who received a booster shot from Moderna or Pfizer was 6.5 times lower than that seen with the original virus.

Anthony Fauci, America’s most renowned Covid physician in America, insists that booster shots can still provide extremely high protection against Omicron-related hospitalisations and deaths.

Yesterday, Professor Chris Whitty from England was quoted as saying that booster jabs may make Britons more protected against Omicron than two doses of the Delta strain. 

According to data from South Africa and the UK, people who received two doses Pfizer vaccine six months apart should be protected against Omicron Disease at 70%.

Columbia researchers found that all four major Covid vaccines, (L-R) Pfizer, Moderna, Johnson & Johnson and AstraZeneca, failed to consistently provide adequate protection against the Omicron variant on their own. People jabbed with Pfizer produced 21 times less antibodies against Omicron, while protection from Moderna fell nine-fold. And neutralising antibodies from AstraZeneca and Johnson & Johnson were almost indetectable. People who had been triple-jabbed (far right graph) with Pfizer and Moderna showed a 6.5-fold drop in neutralising antibodies against Omicron, compared to the levels recorded when their blood was exposed to the Wuhan strain

Columbia researchers found that all four major Covid vaccines, (L-R) Pfizer, Moderna, Johnson & Johnson and AstraZeneca, failed to consistently provide adequate protection against the Omicron variant on their own. Pfizer users produced 21x more antibodies to Omicron than those who were injected with Moderna, but protection by Moderna was nine times lower. And neutralising antibodies from AstraZeneca and Johnson & Johnson were almost indetectable. Triple-jabbed with Moderna (far left graph) showed a 6.5 fold drop in neutralising antibodies for Omicron compared to levels that had been recorded before they were exposed to the Wuhan-strain strain.

A separate study by researchers at the Ragon Institute of MGH, MIT and Harvard also found two doses of vaccine are less effective against Omicron. However, their study showed third doses bring neutralising antibodies back to the level they were against the Delta variant. The graphs show neutralising antibody levels against the original version of Covid compared to Delta (left) and Omicron (right). The dotted black line shows antibody levels after two jabs, while the solid black line shows antibody protection after three jabs. The booster line is much steep against Omicron, meaning that third doses there is higher protection after three jabs, the researchers said

In a separate study, researchers from Harvard, MIT and Ragon Institute found Omicron was less effective than two different doses of vaccine. Their study found that third-dose vaccines produce neutralizing antibodies at the same level as the Delta version. Below are graphs showing neutralising antibodies levels against Covid original (left), and Omicron. (right). The solid black line indicates antibody protection after three shots. While the dotted line represents antibody levels following two jabs. Researchers stated that Omicron is more resistant to boosters than Omicron. This means there’s greater protection with third jabs.

MailOnline spoke to Professor James Naismith of National Research Centre the Rosalind FranklinInstitut, about the results of the study. He said that although the findings echo those of Omicron, they should be considered serious. However, antibodies are only one part of the body’s reaction to Covid infections. 

He stated that Omicron was extremely adept at getting around the immune response.  

Omicron can infect anyone without a booster. The number of cases will increase rapidly.

Professor Naismith explained that antibodies are not all or nothing. He said that a win of 10 is equally good as an extra-time win of 1 nil.

London’s Omicron hotspot London’s Covid Wave is in full swing for EVERY age except the children

Official figures show that covid cases have been rising among all ages, except for young Omicron-hotspot London children. This is a clear indication of the danger facing the NHS in the next weeks.

Super-mutants are already dominating the capital. Tens of thousands of workers remain at home to prevent being isolated over Christmas.

According to data from the Department of Health, London now has the same number of cases as January last year. London was hit hard by the Alpha variant of HIV and placed under more severe measures than other parts of the country.

London’s current crisis began with teenagers and older adults aged between 20 and 30. They were already experiencing an uptake in cases two weeks before the super-infectious strain was discovered. 

MailOnline analysis shows that infections started rising in the 60s and beyond days following Omicron’s discovery in Britain. 

The UK Health Security Agency published data today that showed the capital is now home to the 25 most rapidly growing areas in England, which was another alarming sign. 

Experts agree that capital’s crisis will slow down as the virus simply runs out of room. This is despite dire warnings being issued by Professor Chris Whitty, Boris Johnson, and others urging people to prioritize important events and social gatherings in the coming days.

He said that boosting people with antibodies higher than normal does provide better protection from infection. Think of the booster like a supersub. 

Professor Naismith stated that people also have an innate immune system and a T-cell response to vaccinations or other infections, which provide protection.

He stated that 1,000 Omicron-infected patients in the UK could result in many hospitalisations. 

“I know it will be lower than the first wave. I really hope it will be more than Delta.”

In less than a fortnight, clear-cut evidence will show the effectiveness of boosters against the super-mutant UK variant. 

According to the UK Health Security Agency, there must be at least 250 Omicron-equipped patients before estimates of vaccine effectiveness can be made. 

Only 16 Britons have been diagnosed with this variant so far in the UK. However, it is believed that the number of cases may be lower than expected as not all variant-positive tests can be analysed. 

It comes as the UK’s daily Covid cases yesterday soared to their highest level for the second year in a row, with 88,376 positive tests reported. On Wednesday, the identification of 78,610 cases was possible. In January, the previous record was at 68.053.

A turbo-charged booster programme is dishing out third doses in a bid to limit the impact of the Omicron wave, with 745,183 administered yesterday, the most third doses in a single day. 

Scientists believe the high-tech jabs can increase immunity against the severe illnesses, hospitalisations, and deaths caused by the mutant strain. However, the effects of the jabs on transmission are unlikely to be significant.  

The Colombia researchers said blood samples showed Omicron triggered 32 times less neutralising antibodies compared to the original virus strain.  

Even blood samples from people boosted with Pfizer or Moderna — the vaccines being used for third doses in the UK — showed the vaccines had ‘diminished’ neutralising activity against Omicron. 

The neutralizing antibodies to Omicron were 6.5 times lower in people triple-jabbed using Moderna and Pfizer than the levels seen after they were exposed to the Wuhan-type strain. 

Monoclonal antibodies treatments were also examined by the team and their efficacy was found to be ‘abolished’ or impaired against this variant.

These findings could indicate that the Ronapreve and Ronapreve treatments, which are already approved for use in the UK, may not be as effective. GSK and Pfizer claim that their latest antibody treatments against Omicron should be effective, although this is yet to be proven.  

The Columbia University researchers said four of Omicron’s spike mutations — S371L, N440K, G446S, and Q493R — make it better at resisting antibody protection. 

However, it contains 32 mutations of its spike protein. Many of these have been called unusual. Scientists are investigating their effects on immunity.  

Researchers warned that the Omicron variant poses a threat to several existing Covid therapies and vaccines.    

Professor Whitty spoke to members of the Health and Social Care Committee and stated that the ideal scenario was for six percent of Omicron-infected over-65s to be admitted, which is the same as Delta. 

An example: In the second and first waves, when vaccines were not available, hospitalization rates among those infected in this age group were 22 percent.

Prof Whitty stated that Omicron could be more beneficial than two vaccines with Delta severe diseases.

Professor Whitty warns that the end of an endless cycle of restriction in Britain won’t come until 2023, when Britain will be free from its restrictions.

Britain should expect to suffer another 18 months of Covid misery, Chris Whitty said today.

Chief medical officer stated that he expected a universal jab to fight multiple strains of the virus in mid-2023. He also mentioned several antiviral medications, which will do the heavy lifting for the NHS.

He did admit that ministers would have to use social restraints if Omicron, a vaccine-resistant strain of Omicron, threatens to overthrow the health system.

Professor Whitty spoke to the Health and Social Care Select Committee. He stated: “If I project ahead, I would anticipate within a number of years possibly 18 months…we will have polyvalent vaccinations that will cover a greater range [of variants].

“And, we will likely have many antivirals…and a variety other countermeasures. That means that, except for the very rare exception, the vast majority of the heavy lifting can be done by medical measures when we receive a new version.

Vaccine makers have been quietly working on as polyvalent Covid jabs, designed to immunise against multiple strains, but they are all in early development and way off clinical trials.

The 18-month timeline of Professor Whitty is optimistic, compared to many scientists. Nervtag is a subcommittee which feeds into SAGE and last week advised ministers that Covid was a danger to the NHS for at minimum five years. 

Head of the UK Health Security Agency (UKHSA), Dr Susan Hopkins told the MPs that 250 Britons needed to be admitted to Omicron to allow scientists to determine how serious the strain is, and what vaccines might work against it.

There are 16 people hospitalised with the variant, but Professor Whitty warned the true figure will be ‘much bigger’, as not all positive tests among patients have been sequenced to determine which variant they are infected with.   

Harvard, MIT, and Ragon Institute for Medical Genetics (MIT) also discovered that two vaccine doses are not as effective against Omicron. 

The researchers found third doses of neutralizing antibodies to be at the same level as the Delta variant.

American expert, Professor Carl Bergstrom of Washington University, stated that boosters had a greater effect on Omicron than the earlier strains of virus.

He stated that boosters do not increase antibody titres but alter the antibodies to better target Omicron. 

Data from the UK Government revealed that booster jabs can provide up to 75 protection against Omicron-related mild illnesses. 

UKHSA performed a real-world assessment of 581 Omicron-positive people. They also compared the vaccine status with a control group who had tested negative for Delta.

According to the study, Pfizer boosters provide between 70% and 75% protection from mild Omicron disease, regardless of whether a vaccine has been used previously. This compares with Delta’s 95%.

Pfizer can provide only 37% protection for three and a half months, whereas Delta provides 60%. After the same time, two shots of AstraZeneca provided virtually no protection.

Scientists cautioned that AstraZeneca’s data was more reliable than expected due to restrictions in certain age groups, and the use of this vaccine at vulnerable times was common.   

The Omicron virus is spreading to South Africa. Early data shows that it causes about a third less hospitalisations there than Delta. However, two Covid jabs appear to reduce the chance of being admitted. 

According to officials who examined 78,000 Omicron patients in the last month, the likelihood of being hospitalized was one-fifth lower than for Delta. It also rates 29 percent lower than for the original Omicron virus.

As a crude rate, Omicron is currently leading to a third fewer hospital admissions than Delta did during its entire wave — 38 admissions per 1,000 Omicron cases compared to 101 per 1,000 for Delta.

The researchers also found two doses of Pfizer’s vaccine still provide 70 per cent protection against hospital admission or death from Omicron, compared to 93 per cent for Delta.

This is more protection that scientists had feared. However, 30% of the population remains vulnerable to Omicron disease. That’s four times the amount as Delta.


1. South Africa

One lab-based study found that people who are vaccinated using Pfizer produce 40 percent less Omicron antibodies than other varieties.

Twelve people were double-jabbed to Pfizer by researchers at the African Health Research Institute. 

These antibodies can be used to prevent Omicron infection. 

According to researchers, there’s a 40-fold drop in antibody levels that protect against this strain compared to those that defend against variants.

This study focused only on antibodies. They are one component of an immune system that combats the virus. They are not a reliable indicator. 

This strain is unlikely to result in lower immunity against serious illness and hospitalisation, as well as death for those who are exposed. 

Researchers also discovered that Omicron continues to use the ACE2 receptor in cells to infect humans.

Alex Sigal from the AHRI, a virologist, stated that the new variant could be treated with existing vaccines.

2. Sweden

Researchers in Sweden also found that Omicron is being neutralized in a small drop in body ability. This is in contrast to what was feared.

Scientists at the Karolinska Institute in Stockholm found there was an average seven-fold drop in neutralisation potency against Omicron.

It varied among the patients between a one- to 23-fold decrease. 

According to researchers, almost every blood sample tested had some type of Omicron neutralizing antibody.

These findings were based in part on blood samples collected from 17 Stockholm residents, and 17 other hospital employees who were infected previously with the Wuhan strain. 

Benjamin Murrell (assistant professor in computational biology and virus and immunology, was also one of the research team behind the study. Although it’s ‘certainly worse’ than Delta, it’s not quite as severe as we anticipated. 

He stated that the AHRI study had reported a much larger average reduction’. However, he also noted that neutralisation was not lost completely in all samples which is a good sign. 

3. Germany

The third group of German researchers shared their findings. They found that neutralizing antibodies in two doses of vaccines given in the UK were not effective against the strain. 

Sandra Ciesek is a German Center for Infection Research virologist. She tweeted her laboratory findings. These results have yet to be published. They show that after six months, no antibodies were present in the body that can protect against Omicron. 

Even three months later, the people still had only 25% protection against neutralizing antibodies against Omicron, as opposed to 95% protection against Delta. 

According to Dr Ciesek, this means that Omicron is reduced by 37 times compared to Delta. 

She said that the findings prove that Omicron vaccine development’makes sense.

However, Dr Ciesek said that these results “cannot tell anything” about whether or not people are protected against severe illnesses. Other parts of the immune systems play an important role in this protection. 

4. Pfizer

Pfizer’s data are based in part on laboratory studies that used blood from 20 subjects who had either been double-jabbed 3 weeks before or triple-jabbed 1 month ago with the vaccine.

Results showed that third-dose may offer a more powerful protection. This could trigger a 25-fold rise in antibody levels. 

Pfizer and German partner BioNTech produced the jab. Based on comparisons with other variations, the levels corresponded to high effectiveness. 

According to company, a booster jab gave an additional boost in antibody levels. It was able to withstand two doses of the original Wuhan viruses.

After three jabs, the level of Omicron neutralizing antibodies was 154. It was 155 for Omicron strains after only two jabs.

However, the number was 60% lower than those for Delta’s three dosages.

5. US

A study by researchers at Colombia University , which is a pre-print and has not yet been peer-reviewed, said blood samples showed Omicron triggered 32 times less neutralising antibodies compared to the original virus strain. 

People who were injected with Pfizer had 21x less Omicron antibodies, but nine times more protection against Moderna. 

And neutralising antibodies from AstraZeneca and Johnson & Johnson were almost indetectable. 

Even blood samples from people boosted with Pfizer or Moderna — the vaccines being used for third doses in the UK — showed the vaccines had ‘diminished’ neutralising activity against Omicron. 

The neutralising antibodies to Omicron in people triple-jabbled with Moderna and Pfizer had a 6.5-fold decrease when they were exposed to the Wuhan-strain strain.